Inflammation pathway inhibition

"Inflammation pathway inhibition" refers to the therapeutic strategy of blocking key molecular signaling pathways that mediate the inflammatory response. This can involve targeting molecules such as pro-inflammatory cytokines (e.g., TNF-α, IL-6), cell surface receptors, intracellular kinases (JAKs, MAPKs, SYK), and transcription factors (NF-κB, AP-1), among others. While many current and investigational drugs aim to suppress inflammation by inhibiting these pathways, this term is not specific to a single molecule or class, encompassing a wide range of possible intracellular and extracellular targets. The strategy is clinically important for autoimmune diseases, chronic inflammatory diseases, and other conditions where pathological inflammation plays a role, but the specificity, biomarker selection, and safety profile all depend on the precise molecular target within these pathways.

Other names

inflammation inhibitioninhibition of inflammatory pathwaysanti-inflammatory pathway blockade

Varies depending on specific drug and pathway; examples include: Inhibition of pro-inflammatory cytokine signaling (e.g., TNF-α, IL-6, IL-1β); Inhibition of kinases (e.g., JAKs, MAPKs, SYK); Blockade of leukocyte recruitment and function; Suppression of transcriptional activation (e.g., NF-κB inhibition)